Loading
Life sciences · Journal article
Advanced Science · August 10, 2026
Raises a question worth testing. It does not answer one.
Corramycin is a natural product shown to kill both drug-sensitive and fluoroquinolone-resistant M. tuberculosis in vitro through a novel DNA gyrase poisoning mechanism, revealed by cryo-electron microscopy. The compound's unique binding mode and activity against resistant strains represent an early-stage mechanistic discovery with potential as a research lead, but lacks any animal or human clinical data.
In vitro screening and structural characterization study. M. tuberculosis strains, including drug-sensitive and fluoroquinolone-resistant isolates, in vitro.. Intervention: Corramycin, a natural product from myxobacterial extract library..
Corramycin exhibits potent bactericidal activity against both drug-sensitive and drug-resistant M. tuberculosis. Corramycin induces DNA double-strand breaks through DNA gyrase poisoning. Cryo-electron microscopy structure shows corramycin binds to M. tuberculosis gyrase at a site overlapping fluoroquinolone binding site, locking gyrase in inactive conformation.
No toxicity, pharmacokinetics, or safety data in any system.
This is a preclinical discovery with no human clinical relevance at present. Researchers may consider corramycin as a potential scaffold for antibiotic development; clinicians should not anticipate near-term therapeutic use.
Mechanistic discovery of a natural product's antibacterial action in vitro and structural characterization, without clinical efficacy or safety data in humans.
As stated by the source record.
This is a preclinical discovery with no human clinical relevance at present. Researchers may consider corramycin as a potential scaffold for antibiotic development; clinicians should not anticipate near-term therapeutic use.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Despite significant advancements in drug development and discovery, tuberculosis remains one of the world's deadliest infectious diseases. The rise and global spread of multidrug-resistant strains underscore a critical need for new antibiotics with distinct mechanisms of action. Screening of a myxobacterial extract library uncovered the previously unrecognized antitubercular activity of corramycin, a natural product with potent bactericidal activity against both drug-sensitive and -resistant Mycobacterium tuberculosis. Corramycin enters the bacterial cell by exploiting multiple transport systems, and induces DNA double-strand breaks through a novel form of DNA gyrase poisoning. The cryo-electron microscopy structure of M. tuberculosis gyrase in complex with corramycin reveals that the natural product targets a site overlapping with the binding site of synthetic fluoroquinolones, thereby locking the gyrase in an inactive conformation and preventing re-ligation of DNA. Importantly, its unique mode of binding allows corramycin to overcome fluoroquinolone resistance, highlighting its promise as a novel antibiotic scaffold to address the antimicrobial resistance crisis.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.